Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Clinical trial NCT01671774 · COMPLETED

Trial details

NCT number: NCT01671774
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

CLDN18.2-positive Gastric Adenocarcinoma CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction CLDN18.2-positive Adenocarcinoma of Esophagus

Start date: 2012-10-16
Primary completion: 2014-10-13
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.